AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

26.800

+0.1800.68%

Volume:1.11M

Turnover:29.80M

Market Cap:9.06B

PE:185.34

High:27.170

Open:26.880

Low:26.360

Close:26.620

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Ltd - Does Not Expect Any Material Impact on Its Business or Supply Chain as Result of International Trade Tariffs

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Responds to Recent U.S. Government Actions

THOMSON REUTERS

2 top quality ASX 200 shares to buy after the market selloff

Telix Pharmaceuticals Appoints Chief Technology Officer

MT Newswires Live

10 ASX shares to buy after the market selloff

Bell Potter names the best ASX 200 stocks to buy in April

Press Release: Anne Whitaker Appointed as Non-Executive Director

3 exciting ASX growth shares with massive long-term potential

Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma

MT Newswires Live

Telix Pharmaceuticals Begins Early Trial of Soft Tissue Sarcoma Therapy

MT Newswires Live

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires Live

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Tariff Uncertainty, Lowered FedEx Outlook

MT Newswires Live

Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

THOMSON REUTERS

Australian Shares End Week Flat; Nine Entertainment Explores AU$1.76 Billion Domain Holdings Australia Stake Sale to CoStar

MT Newswires Live

ASX Midday Sector Update: Consumer Staples Stocks Surge, Healthcare Sector Struggles

MT Newswires Live

BRIEF-Telix Pharmaceuticals Says FDA Approves New Prostate Cancer Imaging Agent Gozellix

Friday’s HotCopper Trends: Telix bags FDA approval, Paladin’s mine drenched | March 21, 2025

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":26.8,"timestamp":1746771120000,"preClose":26.62,"halted":0,"volume":1111086,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274906865,"shares":337878497,"eps":0.1446,"marketStatus":"Market Closed","change":0.18,"latestTime":"05-09 16:12:00 AEST","open":26.88,"high":27.17,"low":26.36,"amount":29801371,"amplitude":0.030428,"askPrice":26.83,"askSize":8954,"bidPrice":26.76,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":26.62,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.6589934372030005,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274906865,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.6589934372030005,"shares":337878497,"dividePrice":0,"high":27.17,"amplitude":0.030428,"preClose":26.62,"low":26.36,"week52Low":14.42,"pbRate":"15.94","psRate":"11.56","week52High":31.97,"institutionHeld":0,"latestPrice":26.8,"committee":-0.713029,"eps":0.1446,"divideRate":0,"volume":1111086,"delay":0,"ttmEps":0.1446,"open":26.88,"prevYearClose":24.61,"prevWeekClose":29.32,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":29.32,"twentyDayClose":24.81,"sixtyDayClose":27.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525056766","title":"Telix Pharmaceuticals Ltd - Does Not Expect Any Material Impact on Its Business or Supply Chain as Result of International Trade Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525056766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525056766?lang=en_us&edition=fundamental","pubTime":"2025-04-07 11:37","pubTimestamp":1743997071,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL008:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2525056750","title":"Telix Pharmaceuticals Ltd - Responds to Recent U.S. Government Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2525056750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525056750?lang=en_us&edition=fundamental","pubTime":"2025-04-07 11:37","pubTimestamp":1743997071,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL008:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2525035365","title":"2 top quality ASX 200 shares to buy after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2525035365","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525035365?lang=en_us&edition=fundamental","pubTime":"2025-04-07 08:33","pubTimestamp":1743985980,"startTime":"0","endTime":"0","summary":"The ASX 200 index is crashing on Monday following an equally brutal selloff on Wall Street on Friday. While it certainly is a tough time for ASX investors, it could also be one of the best buying oppo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/07/2-top-quality-asx-200-shares-to-buy-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","BK7067","RMD.AU","ROE","BK7501","BK7007"],"gpt_icon":1},{"id":"2525869380","title":"Telix Pharmaceuticals Appoints Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525869380","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525869380?lang=en_us&edition=fundamental","pubTime":"2025-04-07 07:48","pubTimestamp":1743983321,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) appointed Paul Schaffer as chief technology officer, according to a Monday statement by the company.Schaffer has been the CTO at Artms, which Telix acquired last year, for the past seven years, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"gpt_icon":0},{"id":"2525575822","title":"10 ASX shares to buy after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2525575822","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525575822?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:07","pubTimestamp":1743797220,"startTime":"0","endTime":"0","summary":"The recent share market selloff has rattled investor confidence — but for those thinking long term, it could be a gift in disguise. When share prices drop across the board, it often has less to do wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/05/10-asx-shares-to-buy-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0795875169.SGD","WTC.AU","BK7511","LU0971096721.USD","LU2237443978.SGD","TLX.AU","LU2471134879.HKD","LU2133065610.SGD","WOW.AU","LU2237443382.USD","BK7040","LU2028103732.USD","LU0225283273.USD","LOV.AU","LU2089283258.USD","TNE.AU","IE00B19Z3581.USD","BK7155","GMG.AU","LU1732800096.USD","BK4516","BK7016","LU1868836914.USD","LU0061475181.USD","LU2471134796.USD","BK4588","MQG.AU","LU0795875086.SGD","LU2750360641.GBP","LU1868836591.USD","BK7007","LU1868836757.USD","LU2237443549.SGD","BK7099","LU1791807156.HKD","LU0251142724.SGD","XRO.AU","CSL.AU","LU1074936037.SGD","LU0314104364.USD","LU1989772840.SGD","BK4581","BK7128","LU1162221912.USD","LU1989772923.USD","LU2237443465.HKD","BK4127","BK4552","RMD.AU","LU1732799900.SGD"],"gpt_icon":0},{"id":"2524381221","title":"Bell Potter names the best ASX 200 stocks to buy in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2524381221","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524381221?lang=en_us&edition=fundamental","pubTime":"2025-04-04 11:21","pubTimestamp":1743736862,"startTime":"0","endTime":"0","summary":"If you are looking for ASX 200 stocks to buy in April after recent weakness, then it could be worth listening to what analysts atBell Potterare saying. That's because the broker has just revealed its ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/bell-potter-names-the-best-asx-200-stocks-to-buy-in-april/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7104","BK7067","EVN.AU","BK7506","TLX.AU"],"gpt_icon":0},{"id":"2524212621","title":"Press Release: Anne Whitaker Appointed as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2524212621","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524212621?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:13","pubTimestamp":1743718380,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025  -- Telix Pharmaceuticals Limited  today announces the appointment of Anne Whitaker as a Non-Executive Director  based in the United States, effective 7 April 2025 .Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC  and is Chair at QurAlis Corporation.Telix Chairman, H Kevin McCann AO, said, \"Anne is an outstanding addition to our Board. She brings industry-relevant expertise across commercial risk management, mergers and acquisitions and Nasdaq governance, with experience across a vast range of global, growth-focused healthcare companies. The Board looks forward to Anne's con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0426417589.USD","BK7067","LU0994945656.USD","BK4121","ICLR","LU1267930813.SGD","TSYW.SI","LU0882574055.USD","LU2324357040.USD","BK4543","LU0728928796.USD","USJW.SI","LU0511384066.AUD","MNQmain","LU2265009873.SGD","TQQQ","BK4141","R","GSK.UK","LU0528227936.USD","LU1804176565.USD","LU0792757196.USD","QID","ASX","LU2244417387.USD",".IXIC","NQmain","LU0128525929.USD","LU0069063385.USD","BK4139","LU0289960550.SGD","SQQQ","LU1121112475.USD","LU2362541513.USD","TLX.AU","QLD","TLX","LU2362540622.SGD","LU0426412945.USD","LU1267930573.SGD","NVIW.SI","BK4526","LU1791710400.SGD","GSK","LU0029864427.USD","PSQ","LU2362541273.HKD","USAW.SI","LU0708994859.HKD"],"gpt_icon":1},{"id":"2524339442","title":"3 exciting ASX growth shares with massive long-term potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2524339442","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524339442?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:54","pubTimestamp":1743627240,"startTime":"0","endTime":"0","summary":"If you're looking to invest in the next generation of ASX success stories, sometimes you need to look beyond the usual household names. While the big end of town offers stability, it's often the mid-c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/03/3-exciting-asx-growth-shares-with-massive-long-term-potential/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4023","BK7094","BK4613","BK7016","PME.AU","BK7067","LIF","TLX.AU","360.AU"],"gpt_icon":0},{"id":"2524818124","title":"Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524818124","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524818124?lang=en_us&edition=fundamental","pubTime":"2025-04-02 13:19","pubTimestamp":1743571140,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma , according to a Tuesday statement by the company.The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography , the statement said.TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.The study will inform future therapeutic approaches for treating the disease, the company said.Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.Shares of the company fell 3% on market close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","PET.AU","BK7067","BK7047","BK4192","PET"],"gpt_icon":0},{"id":"2524412989","title":"Telix Pharmaceuticals Begins Early Trial of Soft Tissue Sarcoma Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524412989","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524412989?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:06","pubTimestamp":1743537980,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) administered the first patient dose in an early trial of TLX300-CDx, also known as olaratumab, to treat advanced metastatic soft tissue sarcoma.The trial aims to evaluate t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2524126511","title":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126511","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126511?lang=en_us&edition=fundamental","pubTime":"2025-04-02 03:30","pubTimestamp":1743535800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 02, 2025  -- Telix Pharmaceuticals Limited  today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx  in patients with advanced, metastatic soft tissue sarcoma  at the Melbourne Theranostic Innovation Centre  in Melbourne, Australia.The aim of the trial is to evaluate the safety, pharmacokinetics, biodistribution and dosimetry, and establish the optimal dose of TLX300-CDx in patients with advanced STS, prior to therapeutic studies, based on a theranostic approach. As part of the study, it is also expected that the patient dosimetry and target expression characteristics will inform the final selection of therapeutic radionuclide for this candidate, in conjunction with currently active non-clinical radiation biology studies.Telix intends to develop a novel targeted radionuclide therapy, specific for PDGFRα, which could be used to treat patients with STS. Telix holds the exclusive worldwide rights to develop and commercializ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-announces-first-patient-dosed-193000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4526","BK4543","AEIS","ASX.AU","BK7047","PET.AU","BK7039","BK4141","TLX","XKO.AU","IE0031619046.USD","PET","BK4139","IE00B7SZL793.SGD","ASX","BK4157","XJO.AU","IE00B66KJ199.SGD","TLX.AU","XAO.AU","SEC.AU","BK7067","BK4192","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2524119135","title":"ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®","url":"https://stock-news.laohu8.com/highlight/detail?id=2524119135","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524119135?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:49","pubTimestamp":1743511740,"startTime":"0","endTime":"0","summary":"BURNABY, British Columbia, April 01, 2025  -- Telix ARTMS, Inc. , a global leader in radioisotope production technologies, is pleased to announce that the drug master file 1 for gallium-68 production using its QUANTM Irradiation System  cyclotron technology has been referenced for the first time with a United States  Food and Drug Administration  approved product, with Gozellix .This approval will enable radiopharmacies and hospitals using ARTMS’ QIS cyclotron technology and associated targets to produce multi-Curies of 68Ga for use with Gozellix. The expanded distribution radius and increased dose production capacity, compared to existing gallium-based PET tracers, will facilitate broader and more equitable access. In addition, use of ARTMS’ technology is being expanded internationally where regulatory submissions are in preparation. Pharmaceutical companies will be able to reference ARTMS’ standardized isotope production technology with their approved drugs, helping to localize and s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/artms-drug-master-file-gallium-124900554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4543","TLX","DMF","SEC.AU","BK7039","BK4526","ASX","ASX.AU","TLX.AU","BK4141","BK7067","BK4139"],"gpt_icon":0},{"id":"2521281516","title":"Sector Update: Health Care Stocks Steady Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281516?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562696,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Friday as the iShares Biotechnology ETF  was inactive and the Health Care Select Sector SPDR Fund  was slightly lower recently.Alnylam Pharmaceuticals  shares rose past 4% after the company said the US Food and Drug Administration has approved the supplemental new drug application for its heart drug Amvuttra.Telix Pharmaceuticals  shares advanced nearly 4% after the company said the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.Dyne Therapeutics  appointed Erick Lucera as chief financial officer, effective March 31. Dyne Therapeutics shares were nearly 7% lower pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY","BK4505","BK4585","DYN","BK4548","BK4588","BK4139","BK7067","IBB","TLX.AU","XLV","TLX","BK4581"],"gpt_icon":0},{"id":"2521855132","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Tariff Uncertainty, Lowered FedEx Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2521855132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521855132?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:28","pubTimestamp":1742560125,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) retreated 0.3% in Friday's premarket activity, amid escalating tariff c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLE","UNG",".DJI","XLK","IGV","FAS","VHT","XLV","VIS","SOXX","FAZ","IYK","XLI","IYJ","SLV","TLX","EEM","IYH","XLY","BITO","SPY.AU","XLP","IBB","VHT.AU","IYW","EXI","FDN","TD","EQR","RTH.AU","SPY","WKEY","TLX.AU","FDX","XRT","IGM","RTH","XSD","IYE","USO",".SPX","PMR","IVV","IPK","XLF",".IXIC"],"gpt_icon":1},{"id":"2521262401","title":"Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2521262401","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521262401?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:58","pubTimestamp":1742554680,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval.The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food and Drug Administration approved the new drug application for Gozellix.Gozellix helps with advanced imaging for prostate cancer, making it easier to detect. It provides a longer shelf life and an extended distribution radius compared to existing gallium-based imaging products, Telix said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","TLX.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2521093804","title":"FDA Approves New Prostate Cancer Imaging Agent Gozellix®","url":"https://stock-news.laohu8.com/highlight/detail?id=2521093804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521093804?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:30","pubTimestamp":1742553045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA4W7SSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2521425413","title":"Australian Shares End Week Flat; Nine Entertainment Explores AU$1.76 Billion Domain Holdings Australia Stake Sale to CoStar","url":"https://stock-news.laohu8.com/highlight/detail?id=2521425413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521425413?lang=en_us&edition=fundamental","pubTime":"2025-03-21 14:16","pubTimestamp":1742537771,"startTime":"0","endTime":"0","summary":"Australian shares closed the week flat with a positive tilt, even as other Asian markets fell, as global central banks paint an uncertain outlook amidst rising tariff concerns.The S&P/ASX 200 Index wa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","LU0320765059.SGD","LU0390134368.USD","BK7503","BK7501","TLX.AU","BK4079","LU0672654240.SGD","BK7040","XKO.AU","LU2210150020.SGD","XJO.AU","IE0004445239.USD","LU2210149790.SGD","BK7067","BK4548","COL.AU","IE0009356076.USD","BK7052","BK7511","BK7002","DHG.AU","LU0708995401.HKD","BK4588","LU1267930730.SGD","NEC.AU","LU0109391861.USD","BK4123","BK7082","CSGP","BK4585","LU2095319765.USD","WOW.AU"],"gpt_icon":0},{"id":"2521744367","title":"ASX Midday Sector Update: Consumer Staples Stocks Surge, Healthcare Sector Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2521744367","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521744367?lang=en_us&edition=fundamental","pubTime":"2025-03-21 10:39","pubTimestamp":1742524777,"startTime":"0","endTime":"0","summary":"Consumer staples stocks surged 3.3% at midday Friday after a report from the competition regulator found that supermarket giants Coles Group , Woolworths Group , and ALDI are some of the most profitable supermarket businesses among global peers.The Australian Competition and Consumer Commission , found that the supermarket sector remains highly concentrated, with Coles and Woolworths dominating the market and ALDI providing limited price competition. It outlined 20 recommendations to address rising prices, market concentration, and supplier challenges.On the other hand, the healthcare sector struggled, falling 0.72%. Uncertainty around US policy weighed on market sentiment on Wall Street.Telix Pharmaceuticals  said that the US Food and Drug Administration has approved its New Drug Application for Gozellix, the company's prostate-specific membrane antigen positron emission tomography  imaging agent for prostate cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WOW.AU","BK7067","SPLS","BK7501","BK7082","BK7511","BK4137","COL.AU","TLX.AU","HCSG","BK7040"],"gpt_icon":0},{"id":"2521414034","title":"BRIEF-Telix Pharmaceuticals Says FDA Approves New Prostate Cancer Imaging Agent Gozellix","url":"https://stock-news.laohu8.com/highlight/detail?id=2521414034","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521414034?lang=en_us&edition=fundamental","pubTime":"2025-03-21 09:22","pubTimestamp":1742520126,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says FDA Approves New Prostate Cancer Imaging Agent GozellixMarch 21 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:FDA APPROVES NEW PROSTATE CANCER IMAGING AGENT GOZELLIXFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q30RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2521412696","title":"Friday’s HotCopper Trends: Telix bags FDA approval, Paladin’s mine drenched | March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521412696","media":"The Market Herald","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521412696?lang=en_us&edition=fundamental","pubTime":"2025-03-21 09:22","pubTimestamp":1742520120,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,922 points on Friday.Staples has been the best-performing sector, up 3%, followed by Industrials and Utilities, both up 0.5%.Health Care has been the worst-performing, down 0.6%, followed by Information Technology, down 0.5%, and Energy, down 0.33%.Telix Pharmaceuticals  has been the most watched on HotCopper forums today following the U.S. FDA’s approval for its New Drug Application  for Gozellix, the company’s next-generation imaging agent for prostate cancer.Also trending is CZR Resources  after inking a deal with Robe River Joint Venture  to divest CZR’s interest in several tenements including the Robe Mesa Iron Ore project for cash consideration of A$75 million.Rounding out the most discussed today has been Paladin Energy  after its Langer Heinrich Mine wasimpacted by “unseasonal” heavy rains in Namibia.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fridays-hotcopper-trends-telix-bags-fda-approval-paladins-mine-drenched-march-21-2025-2025-03-21/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7509","PDN.AU","00495","BK1258","BK7083","BK1229","CZR.AU","TLX.AU","BK7067","BK7129"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}